ArticleIrish journal of medical science2026
The effect of beta-blockers in heart failure with preserved ejection fraction and atrial fibrillation: systematic review and meta-analysis.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) frequently coexist and together confer a substantially elevated risk of adverse cardiovascular outcomes. Despite the widespread clinical use of beta-blockers for rate control in this population, their prognostic impact remains unresolved, with existing evidence derived predominantly from observational cohorts subject to confounding by indication.
aimsTo evaluate the association of beta-blocker therapy with all-cause mortality, cardiovascular mortality, heart failure hospitalization, and composite outcomes in patients with coexisting HFpEF and AF through a systematic review and meta-analysis.
methodsOnline databases (MEDLINE and Scopus) were searched from inception through March 2026 for studies reporting on the effects of beta-blockers in patients with HFpEF and AF. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using the DerSimonian and Laird random-effects model. Heterogeneity was quantified using the I
resultsNine studies were included (n = 31,888; beta-blocker group n = 24,683; control n = 7,205). Beta-blocker therapy was associated with a statistically significant reduction in all-cause mortality (HR: 0.88; 95% CI: 0.83-0.93; P < 0.0001; I
conclusionsIn patients with HFpEF and concomitant AF, beta-blocker therapy is associated with significant reductions in all-cause and cardiovascular mortality. No significant benefit was observed for heart failure hospitalization or composite outcomes in primary analyses, though sensitivity analyses were supportive. These findings, derived from observational data, support a permissive clinical approach to beta-blocker use in this population, particularly for rate control in those with elevated heart rates. Adequately powered randomized controlled trials specifically targeting HFpEF with AF are urgently needed to establish causal efficacy.
Indexed as
Identifiers
42825854What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.